Breast Cancer Research and Treatment

, Volume 121, Issue 2, pp 311–321

Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells

Authors

  • Ying Qu
    • Department of Molecular Oncology, John Wayne Cancer InstituteSaint John’s Health Center
    • Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin HospitalShanghai Jiaotong University School of Medicine
  • Jinhua Wang
    • Department of Molecular Oncology, John Wayne Cancer InstituteSaint John’s Health Center
  • Myung-Shin Sim
    • Department of Biostatistics, John Wayne Cancer InstituteSaint John’s Health Center
  • Bingya Liu
    • Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin HospitalShanghai Jiaotong University School of Medicine
  • Armando Giuliano
    • Department of Molecular Oncology, John Wayne Cancer InstituteSaint John’s Health Center
  • James Barsoum
    • Synta Pharmaceuticals Corporation
    • Department of Molecular Oncology, John Wayne Cancer InstituteSaint John’s Health Center
Preclinical study

DOI: 10.1007/s10549-009-0470-6

Cite this article as:
Qu, Y., Wang, J., Sim, M. et al. Breast Cancer Res Treat (2010) 121: 311. doi:10.1007/s10549-009-0470-6

Abstract

Elesclomol is a small-molecule investigational agent that selectively induces apoptosis in cancer cells by increasing oxidative stress. Elesclomol plus paclitaxel was shown to prolong progression-free survival compared with paclitaxel alone in a phase II clinical trial in patients with metastatic melanoma. However, the therapeutic potential of elesclomol in human breast cancer is unknown, and the signaling mechanism underlying the elesclomol effect is unclear. Here, we show that elesclomol alone modestly inhibited the growth of human breast cancer cells but not normal breast epithelial cells. Elesclomol potentiated doxorubicin- or paclitaxel-induced apoptosis and suppression of breast cancer cell growth. While both c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase were activated by elesclomol, elesclomol-induced apoptosis was only in part mediated by JNK1. The additive effect of elesclomol on chemotherapy drug-induced apoptosis was associated with increases in cleaved caspase-3, p21Cip1, and p27Kip1 and decreases in the Inhibitor of Apoptosis Protein levels and NF-κB activity. We also found that Akt/Hsp70 survival signaling was induced by elesclomol, which may reflect a cellular feedback mechanism. Blockade of Akt activation using a small-molecule inhibitor enhanced elesclomol-elicited apoptosis, while expression of a hyperactive Akt abolished the elesclomol effect. These data suggest that elesclomol’s interaction with conventional chemotherapeutic and Akt-targeting agents may be exploited to induce apoptosis in breast cancer cells, and clinical trials of combined treatment of elesclomol and chemotherapy drugs or Akt-targeting agents in breast cancer patients, especially the estrogen receptor negative subgroup, may be warranted.

Keywords

AktApoptosisChemotherapyElesclomolJNKReactive oxygen species

Supplementary material

10549_2009_470_MOESM1_ESM.pdf (562 kb)
Supplementary material 1 (PDF 563 kb)

Copyright information

© Springer Science+Business Media, LLC. 2009